Posoleucel clinical trials
How each study uses posoleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
AlloVir (4)
Studies
Open first, then newest update. How each study uses posoleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell TransplantTerminatedPhase 2/3AlloVirNCT05305040Written as Posoleucel (ALVR105)
- Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)TerminatedPhase 3AlloVirNCT04390113Written as Posoleucel (ALVR105)
- Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell TransplantCompletedPhase 2/3AlloVirNCT04693637Written as Posoleucel (ALVR105)
- Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell TransplantationTerminatedPhase 3AlloVirNCT05179057Written as Posoleucel
Codes
What other systems call posoleucel · ClinicalTrials.gg INT016227
- UNII (FDA) CH357NR3E3POSOLEUCELOne source FDA
- NCI Thesaurus C172802PosoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CH357NR3E3 | POSOLEUCEL | One source FDA |
| NCI Thesaurus | C172802 | Posoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.